Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Revenue of Vincerx Pharma, Inc. (VINC)
Revenue in 2023 (TTM): $
According to Vincerx Pharma, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Vincerx Pharma, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-915,000 | $-42,609,000 | $-40,157,000 | $-40,157,000 |
| 2022 | $ | $-939,000 | $-68,668,000 | $-65,367,000 | $-57,160,000 |
| 2021 | $ | $-340,000 | $-62,656,000 | $-39,306,000 | $-15,608,000 |
| 2020 | $ | $-172,996 | $-10,714,000 | $-10,722,000 | $-10,730,000 |
| 2019 | $ | $-172,996 | $9 K | $-45,000 | $-45,000 |